The frequency of CD4 + CD25 + FoxP3 + CD127 − cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy
- 27 April 2020
- Vol. 75 (10), 2685-2686
- https://doi.org/10.1111/all.14342
Abstract
No abstract availableFunding Information
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (STM.A020.17.053)
- Narodowe Centrum Nauki (GR‐775/NCN/2011)
This publication has 4 references indexed in Scilit:
- Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up seasonJournal of Allergy and Clinical Immunology, 2018
- Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkersJournal of Allergy and Clinical Immunology, 2017
- Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cellsImmunological Reviews, 2017
- Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb studyJournal of Allergy and Clinical Immunology, 2016